Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center

Journal of Clinical Immunology
Eun Sang YiKeon Hee Yoo

Abstract

We aimed to report our single-center experience of allogeneic hematopoietic cell transplantation (HCT), which has been the only curative option for certain patients with lethal primary immunodeficiencies (PIDs). We summarized the results of HCT performed for patients with PIDs for 11 consecutive years from 2006 to 2016 at Samsung Medical Center, Seoul, Korea. Twenty-six patients with PIDs received HCT. Most had chronic granulomatous disease (42.3%), Wiskott Aldrich syndrome (15.4%), or severe combined immunodeficiency (11.5%). Nine patients (34.6%) received HCT during the former half period and 17 patients (65.4%) during the latter half period. Donor types were categorized as: matched sibling donor (n = 5), unrelated donor (n = 17), and familial mismatched donor (FMMD) (n = 4). Unrelated HCT and FMMD transplantation were increasingly performed in the latter half period compared to the first (5 vs. 16, P = 0.034). Five patients experienced initial engraftment failure, but all of them were eventually engrafted after additional HCTs. The 3-year probability of overall survival was 72.0%. Seven patients (26.9%) died, and the causes of death were bacterial sepsis (n = 4), pneumonia (n = 1), chronic graft-versus-host disease (GVHD) (n...Continue Reading

References

Jan 24, 2006·Blood Reviews·Mitchell E Horwitz, Keith M Sullivan
Aug 3, 2010·The Journal of Allergy and Clinical Immunology·Andrew R GenneryUNKNOWN European Society for Immunodeficiency
May 17, 2011·British Journal of Haematology·Tomohiro MorioUNKNOWN Japanese Cord Blood Bank Network
Feb 7, 2012·Blood·Juliana F FernandesUNKNOWN Eurocord and Inborn Errors Working Party of European Group for Blood and Marrow Transplantation
Oct 29, 2013·Lancet·Tayfun GüngörUNKNOWN Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation
Jan 1, 2014·Pediatric Transplantation·Meerim ParkUNKNOWN Korean Cord Blood Transplantation Working Party
Jul 31, 2014·The New England Journal of Medicine·Sung-Yun PaiRichard J O'Reilly
Aug 5, 2014·Journal of Pediatric Hematology/oncology·Tsung-Yun ChangIou-Jih Hung
Sep 27, 2014·Current Opinion in Allergy and Clinical Immunology·Sung-Yun Pai, Morton J Cowan
May 20, 2015·Journal of Pediatric Hematology/oncology·Sharon Z RoussoPolina Stepensky
Jun 6, 2016·The Journal of Allergy and Clinical Immunology·Linda M GriffithUNKNOWN workshop participants
Jan 7, 2017·World Journal of Transplantation·Nosha Farhadfar, William J Hogan
Apr 16, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James A Connelly
Nov 21, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mary A SlatterPaul Veys

❮ Previous
Next ❯

Citations

Feb 6, 2020·Allergy, Asthma & Immunology Research·Won Kyung KwonEun Suk Kang
Sep 10, 2020·Frontiers in Immunology·Daniel LeungYu Lung Lau
Aug 9, 2019·World Journal of Transplantation·Tatyana Gavrilova
Mar 18, 2020·Genes & Diseases·Rakesh Kumar PilaniaSurjit Singh

❮ Previous
Next ❯

Software Mentioned

FMMDT

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.